M&As this week: Catalent, Ultragenyx Pharmaceutical


Catalent has announced plans to acquire Cook Pharmica for $950m.

The acquisition will strengthen Catalent’s position in the biologics development and analytical services sectors.

Both the acquirer and target entities are pharmaceutical companies based in the US.

"Biopharmaceutical company Ultragenyx Pharmaceutical plans to acquire rare disease company Dimension Therapeutics for $138m."

Biopharmaceutical company Ultragenyx Pharmaceutical plans to acquire rare disease company Dimension Therapeutics for $138m.

The acquisition will strengthen the company’s business and help in accelerating the development of its therapeutics.

Both companies involved in the acquisition are based in the US.